Professional Documents
Culture Documents
Role of Anthracycline in The Therapy of Breast
Role of Anthracycline in The Therapy of Breast
Looking for :
Non anthracycline regimens ,
equally effective , and less toxic
Equal:
(PFS) Prolonged progression free survival
(OS) overall survival .
Controversy .
Expert pro :
1. ,, Anthracycline therapy may be avoidable in EBC
(R.Tuma; JNCI April 2, 2008 )
2. ,,Do we still need Anthracycline,, ? (ASCO
Educational book 2008)
3. Many women could be treated without
Anthra.cycline (S.Jones JNCI, April 2008)
Expert contra:
,,Trial relative small, verry provocative,, very
sheldom change standard care base on 1000 (Edith
Perez)
Stephen E. Jones, MD
Baylor-Sammons Cancer Center, Dallas, TX
US Oncology Research, Houston, Texas
main menu
US Oncology 9735:
Study Design
AC x 4 q3w
Doxorubicin (60 mg/m2)
Cyclophosphamide (600 mg/m2)
n=510
R
TC x 4 q3w
• N=1016 Taxotere (75 mg/m2)
• 71% ER+ Cyclophosphamide (600 mg/m2)
• 48% N–
n=506
Chemotherapy doses based on actual
BSA (no cap)
Eligibility: Stage I, II, or III disease
Chemotherapy given prior to radiation
Tamoxifen for all ER+ patients after
chemotherapy +/- radiation
Jones et al. J Clin Oncol. 2006;24:5381-5387.
Risk Versus Benefit in Context
With USON 9735
TC superiority over AC
(HR=0.67 for DFS)*
(statistically significant)
Only single centre.
*Jones et al. J Clin Oncol. 2006;24:5381-5387; Slamon et al. SABCS 2006. Abstract 52.
Result :
1. Taxanes have improved the effectiveness of several
adjuvant regimens
5. Stay tuned!
main menu
Why AC Remains a Standard
4 cycles of AC became ‘standard’
Until now, no treatment of 4 cycles in length was
superior to AC
2. BCIRG 006: Study Design
4 x AC 4 x Taxotere
60/600 mg/m2 100 mg/m2
ACT
HER2+
(Central FISH) 4 x AC 4 x Taxotere
60/600 mg/m2 100 mg/m2
N+
or high ACTH
risk N-
1 Year Trastuzumab
HR - HR -
HR + HR +
HR - HR -
HR + HR +
p=.0015
p<0.0001 p<.0001
p=.5
Slamon et al. SABCS 2006. Abstract 52.
BCIRG 006: Mean LVEF - All Observations
Second Interim Analysis
66
65
64
TCH
LVEF Points %
63 AC->T
62
61 AC->TH
60
59
58
0 100 200 300 400 500 600 700 800 900 1000
main menu
Critical Question:
Functions
Growth and proliferation
Differentiation
Cell survival
Motility
Angiogenesis
The Topo IIa Gene
Encodes an enzyme which is critical in DNA
replication and function, including RNA transcription
Functions
DNA repair
RNA transcription
DNA replication
DNA segregation, condensation and superhelicity
40 CMF
0 5 10
100 Normal expression of topo protein
p-value=0.6
80
Probability CEF
(%) 60
CMF
40
0 5 10
Time (years)
Disease Free Survival HER2 positive
HER2 negative
main menu
Circumstantial Evidence Linked HER2 Gene
Amplification to Anthracycline Sensitivity
Pre-trastuzumab era
Studies showed superior outcomes with anthracyclines
in patients with HER2-positive disease.
CALGB 8541
NSABP B11
NSABP B15
Intergroup 0100
van Dalen EC et al. Cochrane Database Syst Rev 2006 Ryberg et al. J Clin Oncol. 2007;25:39s ;1029 (abstr)
Cardiotoxicity
100
90
% CHF = X2/Y Mathematical Curve
80
X=n cycles chemotherapy
70 Y
MD Anderson
60 Doxorubicin 50 mg/m2 16
Doxorubicin 60 mg/m2 11.5
50 Epirubicin 90 mg/m2 20
40
Von Hoff
30
20
10
0
0 100 200 300 400 500 600 700 800 900
Cumulative Doxorubicin Dosage (mg/m2)
Ewer et al. J Card Fail. 2005;11
Anthracycline-Associated Heart Failure
100
90
80
• Cumulative dose of doxorubicin
70 • Combination chemotherapy
CHF (%)
60
50 • Prior/concomitant mediastinal radiotherapy
40
MD Anderson • Age
30
Von Hoff
20 • Previous cardiac disease
10
0 • Hypertension
0 100 200 300 400 500 600 700 800 900
Doxorubicin Cumulative Dose (mg/m2)
Anthracycline Cardiotoxicity: How to prevent?
Bolus vs Continuous Infusion Liposomal Doxorubicin
Shapira et al. Cancer 1990; 65: 870-873 O’Brien et al. : Ann Oncol. 2004;15:440-9
Antioxidants
Dexrazoxane (Zinecard)
Anthracyclines Cardiotoxicity
Incidence and Age
100
Doxorubicin Related CHF (%)
90 B < 65 years
80 J > 65 years
70
HR 2.25 (1.04, 4.96)
60 J J J J J J
50 p=.029
B B B B
40
30 J
B
J
20 B
B
10 J
B B
JB JB JB
0 JB JB JB JB
100 200 300 400 500 600 700 800
Cumulative Dose of Doxorubicin (mg/m2)
Swain et al. Cancer. 2003,97:2869.
Trastuzumab Cardiotoxicity:
Risk Factors
Anthracyclines Trastuzumab
Type I Cardiotoxicity Type II Cardiotoxicity
(myocardial damage) (myocardial dysfunction)
Combination chemotherapy Prior/concomitant
anthracyclines
Prior/concomitant
mediastinal radiotherapy
Age > 70 Age > 50 years
Previous cardiac disease Previous cardiac disease
Hypertension Hyperlipidemia
Thomas M. Suter
Swiss Cardiovascular Center, Bern, Switzerland
PACS 01: treatment protocol
6FE100C
S Fluorouracil 500 mg/m² d1
U N=1999 Epirubicin 100 mg/m² d1
R Cyclophosphamide 500 mg/m² d1
G 6 cycles q21d
E
R
R
Y 3FE100C–3Taxotere®
3 cycles of FEC 100 mg/m2 q21d
Stratified by:
followed by
Centre
Age: <50; ≥50 y
3 cycles of Taxotere® 100 mg/m² d1
Nodes: 1–3; ≥4
q21d
Events, n
CHF 4 0
LVEF 4 1
Arrhythmia 2 0
Others§ 2 2
Cardiac death* 1 1
myocardial infarct, dyspnea / pericarditis, menace syndrome
*cardiogenic shock / sudden death
Roché H, et al. Breast Cancer Res Treat. 2004;88 (Suppl 1):S16. Abstract 27.
PACS 01: second cancers
Patients (n) 6FE100C 3FE100C–3T
Second cancers 25 17
Acute myeloid leukemia 3 1
Chronic myeloid leukemia 0 1
Lymphoma/myeloma 1 1
Endometrium 2 (tamoxifen) 1 (tamoxifen)
Ovary 1 3
GI tract 5 5
Head neck tumour 4 1
Skin 3 2
Miscellaneous 6 2
Roché H, et al. Breast Cancer Res Treat. 2004;88 (Suppl 1):S16. Abstract 27.
PACS 01: events, ITT
Patients % 6FE100C 3FE100C–3T p-value*
Roché H, et al. Breast Cancer Res Treat. 2004;88 (Suppl 1):S16. Abstract 27.
PACS 01: 5-year DFS (ITT)
1.00
3FE100C–3T 78.3%
Cumulative probability
0.75 Relapses=482
218 (21.7%)
264 (26.5%)
0.50
6FE100C 73.2%
Roché H, et al. Breast Cancer Res Treat. 2004;88 (Suppl 1):S16. Abstract 27.
PACS 01: DFS by age (ITT)
Age <50 years Age 50 years
1.00 1.00
3FE100C–3T
3FE100C–3T
Kaplan–Meier estimate
0.75 0.75
6FE100C 6FE100C
0.50 0.50
Log-rank p value=0.690 Log-rank p value=0.001
HR (Cox model)=0.98 [0.77–1.25] HR (Cox model)=0.67 [0.51–0.88]
0.25 0.25
Multivariate interaction test
HR=0.66 [0.46–0.95] p value=0.026
0.00 0.00
0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8
Survival time (years) Survival time (years)
Roché H, et al. Breast Cancer Res Treat. 2004;88 (Suppl 1):S16. Abstract 27.
PACS 01: disease free survival by
hazard ratio
3FE100C–3T better 6FE100C better
Age ≥50 years (n=994)
<50 years (n=1004)
Number of positive nodes
≥4 (n=762)
1–3 (n=1236)
Pathological tumour size
≥20 mm (n=1154)
<20 mm (n=673)
Hormone receptor status
HR-negative (n=413)
HR-positive (n=1560)
SBR grade
SBR III (n=773)
SBR II (n=868)
SBR I (n=228)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6
Hazard ratio with 95% CI
Roché H, et al. SABCS 2004, Abstr. 27.
PACS 01: overall survival (ITT)
1.00 3FE100C–3T 90.7%
Death=235
100 (10.0%)
Cumulative probability
0.75
135 (13.5%) 6FE100C 86.7%
0.50
AC x 4→P x 4 76 85